Company news from the 10/17/06 News Brief

Share this article:
Boehringer Ingelheim said it would purchase the US marketing rights to heartburn drug Zantac for $509.5 million as part of Pfizer’s sale of its consumer unit to Johnson & Johnson. In a statement about the purchase, Boehringer Ingelheim Corp. president and CEO J. Martin Carroll said Zantac, an OTC drug, complements the firm’s existing nonprescription franchise, which includes laxative Dulcolax. Zantac will be distributed through the same retail channels as the Dulcolax business, which will allow for increased promotion and marketing efficiencies, Carroll said. Pfizer is selling Zantac to help facilitate FTC approval of the planned, $16.6 billion sale of its Consumer Healthcare business to J&J, a deal expected to close by year’s end. Boehringer Ingelheim GmbH is the world’s biggest closely held drugmaker.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.